Hypoxia mediates mutual repression between microRNA-27a and PPARγ in the pulmonary vasculature

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Kang, Bum Yong ^a   Park, Kathy K ^a   Green, David E ^a   Bijli, Kaiser M ^a   Searles, Charles D ^a   Sutliff, Roy L ^a   Michael Hart, C ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIN 1; MICRORNA; MIRN27 MICRORNA, MOUSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR SP1;

ANIMAL; ANOXIA; BASE PAIRING; BIOLOGICAL MODEL; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; ENDOTHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; LUNG; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PULMONARY ARTERY; PULMONARY HYPERTENSION; RNA INTERFERENCE; VASCULARIZATION;

ANIMALS; ANOXIA; BASE PAIRING; BASE SEQUENCE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTHELIAL CELLS; ENDOTHELIN-1; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPERTENSION, PULMONARY; LUNG; MICE; MICRORNAS; MODELS, BIOLOGICAL; PPAR GAMMA; PULMONARY ARTERY; RNA INTERFERENCE; SP1 TRANSCRIPTION FACTOR;

EID: 84893826747     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079503     Document Type: Article

References (60)

1. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, et al. (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30: 394-403.
2. Lilienfeld DE, Rubin LJ (2000) Mortality from primary pulmonary hypertension in the United States, 1979-1996. Chest 117: 796-800. (Pubitemid 30152223)
3. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, et al. (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153: 1037-1047. (Pubitemid 46809838)
4. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732-1739. (Pubitemid 23170122)
5. He B, Zhang F, Li X, Tang C, Lin G, et al. (2010) Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 74: 1458-1464.
6. Ryerson CJ, Nayar S, Swiston JR, Sin DD (2010) Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 11: 12.
7. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, et al. (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92: 1162-1169. (Pubitemid 36665863)
8. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, et al. (2007) Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292: L885-897. (Pubitemid 46608235)
9. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, et al. (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115: 1275-1284. (Pubitemid 46594772)
10. Kang BY, Kleinhenz JM, Murphy TC, Hart CM (2011) The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 301: L881-891.
11. Kim EK, Lee JH, Oh YM, Lee YS, Lee SD (2010) Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats. Respirology 15: 659-668.
12. Nisbet RE, Bland JM, Kleinhenz DJ, Mitchell PO, Walp ER, et al. (2010) Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol 42: 482-490.
13. Guignabert C, Alvira CM, Alastalo TP, Sawada H, Hansmann G, et al. (2009) Tie2-Mediated Loss of Peroxisome Proliferator-Activated Receptor-{gamma} in Mice Causes PDGF-Receptor {beta}-Dependant Pulmonary Arterial Muscularization. Am J Physiol Lung Cell Mol Physiol 297: L1082-L1090.
14. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, et al. (2008) An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118: 1846-1857. (Pubitemid 351632387)
15. Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y, et al. (2005) [Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats]. Nihon Kokyuki Gakkai Zasshi 43: 283-288.
16. Lu X, Murphy TC, Nanes MS, Hart CM (2010) PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B. Am J Physiol Lung Cell Mol Physiol 299: L559-566.
17. Alastalo TP, Li M, Perez Vde J, Pham D, Sawada H, et al. (2011) Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 121: 3735-3746.
18. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114: 1417-1431. (Pubitemid 44454562)
19. Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114: 464-469.
20. Green DE, Kang BY, Murphy TC, Hart CM (2012) Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates thrombospondin-1 and Nox4 expression in hypoxia-induced human pulmonary artery smooth muscle cell proliferation. Pulm Circ 2: 483-491.
21. Lu X, Bijli KM, Ramirez A, Murphy TC, Kleinhenz J, et al. (2013) Hypoxia downregulates PPARgamma via an ERK1/2-NF-kappaB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells. Free Radic Biol Med 63: 151-160.
22. Caruso P, MacLean MR, Khanin R, McClure J, Soon E, et al. (2010) Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 30: 716-723.
23. Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, et al. (2011) Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am J Respir Crit Care Med 184: 1400-1408.
24. Guo L, Qiu Z, Wei L, Yu X, Gao X, et al. (2012) The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-alpha1C. Hypertension 59: 1006-1013.
25. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, et al. (2012) Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 185: 409-419.
26. Yang S, Banerjee S, Freitas A, Cui H, Xie N, et al. (2012) miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 302: L521-529.
27. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
28. Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, Lehmann U, et al. (2012) Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 31: 764-772.
29. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, et al. (2012) AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J.
30. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, et al. (2011) Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 208: 535-548.
31. Hassan T, McKiernan PJ, McElvaney NG, Cryan SA, Greene CM (2012) Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases. Expert Rev Anti Infect Ther 10: 359-368.
32. Joshi SR, McLendon JM, Comer BS, Gerthoffer WT (2011) MicroRNAs-control of essential genes: Implications for pulmonary vascular disease. Pulm Circ 1: 357-364.
33. White K, Loscalzo J, Chan SY (2012) Holding our breath: The emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm Circ 2: 278-290.
34. Wang J, Song Y, Zhang Y, Xiao H, Sun Q, et al. (2012) Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res 22: 516-527.
35. Jennewein C, von Knethen A, Schmid T, Brune B (2010) MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization. J Biol Chem 285: 11846-11853.
36. Chhabra R, Dubey R, Saini N (2010) Cooperative and individualistic functions of the microRNAs in the miR-23a-27a-24-2 cluster and its implication in human diseases. Mol Cancer 9: 232.
37. Karp X, Ambros V (2005) Developmental biology. Encountering microRNAs in cell fate signaling. Science 310: 1288-1289. (Pubitemid 41698853)
38. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M (2008) A microRNA component of the hypoxic response. Cell Death Differ 15: 667-671. (Pubitemid 351405070)
39. Kleinhenz JM, Kleinhenz DJ, You S, Ritzenthaler JD, Hansen JM, et al. (2009) Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol 297: H1647-1654.
40. Min S, Li L, Zhang M, Zhang Y, Liang X, et al. (2012) TGF-beta-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7. Genes Immun 13: 621-631.
41. Wang W, Zhou D, Shi X, Tang C, Xie X, et al. (2010) Global Egr1-miRNAs binding analysis in PMA-induced K562 cells using ChIP-Seq. J Biomed Biotechnol 2010: 867517.
42. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, et al. (2009) Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 104: 1184-1191.
43. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, et al. (2012) A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 111: 290-300.
44. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, et al. (2012) MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 125: 1520-1532.
45. Gou D, Ramchandran R, Peng X, Yao L, Kang K, et al. (2012) miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol 303: L682-691.
46. Jalali S, Ramanathan GK, Parthasarathy PT, Aljubran S, Galam L, et al. (2012) Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One 7: e46808.
47. Wu C, So J, Davis-Dusenbery BN, Qi HH, Bloch DB, et al. (2011) Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2. Mol Cell Biol 31: 4760-4774.
48. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, et al. (2010) MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 299: L861-871.
49. Kim SY, Kim AY, Lee HW, Son YH, Lee GY, et al. (2010) miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARgamma expression. Biochem Biophys Res Commun 392: 323-328.
50. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S (2007) Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 101: 59-68. (Pubitemid 47094624)
51. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, et al. (2011) Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23-27-24 clusters. Proc Natl Acad Sci U S A 108: 8287-8292.
52. Ji J, Zhang J, Huang G, Qian J, Wang X, et al. (2009) Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett 583: 759-766.
53. Kajimoto K, Naraba H, Iwai N (2006) MicroRNA and 3T3-L1 pre-adipocyte differentiation. RNA 12: 1626-1632. (Pubitemid 44316027)
54. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z (2009) A role of miR-27 in the regulation of adipogenesis. FEBS J 276: 2348-2358.
55. Liu T, Tang H, Lang Y, Liu M, Li X (2009) MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273: 233-242.
56. Urbich C, Kaluza D, Fromel T, Knau A, Bennewitz K, et al. (2012) MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 119: 1607-1616.
57. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-1032.
58. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, et al. (1991) Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84: 2280-2285.
59. Han S, Rivera HN, Roman J (2005) Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells. Am J Respir Cell Mol Biol 32: 350-359. (Pubitemid 40481015)
60. Okada M, Yan SF, Pinsky DJ (2002) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 16: 1861-1868. (Pubitemid 35462604)